Mizoram Reports Highest Tuberculosis Deaths in Six Years
Rising Tuberculosis Fatalities in Mizoram
Aizawl, Jan 12: In 2025, Mizoram recorded 145 deaths due to tuberculosis (TB), marking the highest number of fatalities in the past six years.
During the same year, 2,275 individuals, including 911 women, were diagnosed with TB, showing a slight decline from the 2,291 cases reported in 2024, according to the National TB Elimination Programme under the National Health Mission in Mizoram.
Out of the 2,275 new diagnoses, 1,900 were identified in government healthcare facilities, while the remaining 375 cases were detected in private clinics.
The state has seen a continuous rise in TB-related deaths since 2020, with fatalities increasing from 31 in 2020 to 136 in 2024.
Among the new cases in 2025, 146 individuals were diagnosed with multi-drug-resistant tuberculosis (MDR-TB), and 267 were co-infected with both TB and HIV/AIDS.
Notably, 141 of the new patients were children under the age of 14, and 84% of the patients received successful treatment.
Aizawl district reported the highest number of cases at 1,569, followed by Lunglei with 155 and Kolasib with 138, while Serchhip had the fewest cases at 52.
Over 100 individuals have signed up to support TB patients through the online platform 'Nikshay' as part of the PM TB Mukt Bharat Abhiyan, which aims to enhance community involvement in combating TB and improving treatment outcomes.
Despite a gradual decrease in TB cases, India is still far from eradicating the disease, as highlighted in the Global TB Report 2025 released on November 12.
The report indicated that India had approximately 2.71 million TB cases and over 300,000 deaths in 2024, maintaining its position as one of the highest contributors to the global TB burden.
In 2018, Prime Minister Narendra Modi set a goal to eliminate tuberculosis in India by 2025, five years ahead of the global target. However, the report suggests that the current pace of progress indicates that India is unlikely to meet this ambitious deadline.